title: Vascular graft infections in the intensive care unit: clinical spectrum and prognostic factors.
abstract: OBJECTIVE
  To report clinical characteristics and prognosis of vascular graft infections in Intensive Care Unit (ICU).
  
  
  METHODS
  Thirty seven patients consecutively admitted in ICU for suspected or definite vascular graft infection between January 2006 and June 2009 were included.
  
  
  RESULTS
  Staphylococcus species (n = 18) and enterobacteriae (n = 16) were the most frequent causative organisms. Twenty six patients (70%) needed mechanical ventilation. Further surgical procedures were performed in 7 patients (19%). In case of definite infection, mortality in ICU was 33%. In non survivors, shock (92% vs 42%, p = 0.01), age > 70 years (73% vs 27%, p = 0.04), POSSUM score > 45 (73% vs 27%, p = 0.04) and extra-anatomic bypass (45% vs 14%, p = 0.05) were more frequent, intra-operative volume of red cells transfusion (6 ± 3 vs 3 ± 2 units, p = 0.006) and of fresh frozen plasma (2.8 ± 2.8 vs 0.7 ± 1.2 units, p = 0.02), and SAPS II score (58 ± 26 vs 38 ± 17, p = 0.03) were higher. Proportion of adequate initial antibiotic therapy was similar in survivors and non survivors (91% vs 100%, p = 0.4). Proportion of patients treated with an aminoglycoside tended to be higher in survivors (59% vs 27%, p = 0.07). By multivariate analysis, only shock was associated with death in ICU (AOR: 16.3; 95% CI: 1.7-152.1; p = 0.01).
  
  
  CONCLUSIONS
  Vascular graft infection carries high morbidity and mortality rates in ICU. Extra-anatomic bypass might be associated with higher mortality. Early aminoglycoside prescription might be protective.
authors.affiliation: Service de Réanimation et Maladies Infectieuses, Hôpital Dron, 135 avenue du Président Coty, Tourcoing, France.
authors.forename: Magdalena
authors.initials: M
authors.lastname: Szczot
authors.forename: Agnès
authors.initials: A
authors.lastname: Meybeck
authors.forename: Laurence
authors.initials: L
authors.lastname: Legout
authors.forename: Armelle
authors.initials: A
authors.lastname: Pasquet
authors.forename: Nicolas
authors.initials: N
authors.lastname: Van Grunderbeeck
authors.forename: Joachim
authors.initials: J
authors.lastname: Langlois
authors.forename: Béatrice
authors.initials: B
authors.lastname: Sarraz-Bournet
authors.forename: Patrick
authors.initials: P
authors.lastname: Devos
authors.forename: Olivier
authors.initials: O
authors.lastname: Leroy
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000617:Aminoglycosides / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis / Q000379:methods; D001424:Bacterial Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000401:mortality*; D005260:Female; D006801:Humans; D007362:Intensive Care Units; D008297:Male; D009181:Mycoses / Q000188:drug therapy / Q000453:epidemiology* / Q000401:mortality*; D013530:Surgical Wound Infection / Q000188:drug therapy / Q000453:epidemiology* / Q000401:mortality*; D016019:Survival Analysis; D058017:Vascular Grafting / Q000009:adverse effects*
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents